Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Coughlin Stoia Geller Rudman & Robbins LLP (?Coughlin Stoia?) (http://www.csgrr.com/cases/inyx/) today announced that a class action has been commenced in the United States...
NEW YORK, July 12 /PRNewswire-FirstCall/ -- Inyx, Inc. (OTC:IYXI), reported that the company's Chairman & CEO, Jack Kachkar, M.D., yesterday was approved as the debtor-in-possession lender for...
NEW YORK, April 16 /PRNewswire-FirstCall/ -- Inyx, Inc. (OTC:IYXI) (BULLETIN BOARD: IYXI) , a specialty pharmaceutical company focused on niche drug-delivery technologies and products, reported...
NEW YORK, March 26 /PRNewswire-FirstCall/ -- Inyx, Inc. (OTC Bulletin Board: IYXI), a specialty pharmaceutical company focused on niche drug- delivery technologies and products, reported today...
NEW YORK, March 19 /PRNewswire-FirstCall/ -- Inyx, Inc. (OTC Bulletin Board: IYXI), a specialty pharmaceutical company focused on niche drug- delivery technologies and products, reported today...
NEW YORK, Jan. 31 /PRNewswire-FirstCall/ -- Inyx, Inc. (OTC:IYXI) (BULLETIN BOARD: IYXI) , a specialty pharmaceutical company focused on niche drug-delivery technologies and products, announced...
NEW YORK, Jan. 25 /PRNewswire-FirstCall/ -- Inyx, Inc. (OTC:IYXI) (BULLETIN BOARD: IYXI) , a specialty pharmaceutical company focused on niche drug-delivery technologies and products, reported...
NEW YORK, Dec. 21 /PRNewswire-FirstCall/ -- Inyx, Inc. (OTC:IYXI) (BULLETIN BOARD: IYXI) , a specialty pharmaceutical company focused on niche drug-delivery technologies and products, announced...
NEW YORK, Dec. 7 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (NASDAQ:GNBT), a leader in treating metabolic diseases via drug delivery through the inner lining of the mouth, and...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | -9.9E-5 | -99 | 0.0001 | 0.0001 | 1.0E-6 | 50 | 1.0E-6 | CS |
| 26 | -9.9E-5 | -99 | 0.0001 | 0.0001 | 1.0E-6 | 20 | 1.0E-6 | CS |
| 52 | 0 | 0 | 1.0E-6 | 0.0001 | 1.0E-6 | 3500 | 1.279E-5 | CS |
| 156 | -0.000199 | -99.5 | 0.0002 | 0.0002 | 1.0E-6 | 42930 | 9.648E-5 | CS |
| 260 | -0.001599 | -99.9375 | 0.0016 | 0.0124 | 1.0E-6 | 128501 | 0.00390587 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
